Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Maj 2026

Genmab — Maj 2026

Planlagt Fastgjort Låst Flyttet Genmab
173 Indlæg 1 Posters 239 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote sidst redigeret af
    #164

    Skete med åbning i US i et ellers surt marked.

    1 Reply Last reply
    0
    • R Offline
      R Offline
      Raun
      wrote sidst redigeret af
      #165

      Ja, det er sjovt som aktien springer engang imellem?..... Der skal også snart til at ske noget med kursen. Dette limbo halløj kan ikke blive ved - vi har ASCO om 3 ugers tid....

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote sidst redigeret af
        #166

        Ligner pump and dump der startede med den mærkelige nedtur på regnskabet. Vi må se de kommende dage.

        1 Reply Last reply
        0
        • P Offline
          P Offline
          ProinvestorNEWS
          wrote sidst redigeret af
          #167

          Novo Nordisk er steget 30% på relativ kort tid - men hvad ligger bag stigningen? Hør også om DSV's AI-gevinster frem mod 2030, Genmab-kursfald, høje oliepriser samt meget mere i ugens afsnit af Investeringspodcasten. https://proinvestor.com/boards/132326

          1 Reply Last reply
          0
          • P Offline
            P Offline
            peter12
            wrote sidst redigeret af
            #168

            Interessant artikel om konkurrerende produkt til peto, hvor udvidelsen diskuteres https://seekingalpha.com/article/4904035-bicara-therapeutics-inc-bcax-presents-at-bank-of-america-global-healthcare-conference-2026

            1 Reply Last reply
            0
            • R Offline
              R Offline
              Raun
              wrote sidst redigeret af
              #169

              Tak for den @peter12

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote sidst redigeret af
                #170

                Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6 https://www.sciencedirect.com/science/article/pii/S215226502600042X

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote sidst redigeret af
                  #171

                  Stuck in traffic: a bispecific antibody-mediated immune re-engagement after allogeneic stem cell transplantation https://haematologica.org/article/view/14183 (click on PDF to read article)

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote sidst redigeret af
                    #172

                    University looking to test Dara in lung cancer... https://clinicaltrials.gov/study/NCT06015724 - don't want to bring up Hexabody-CD38 again, but...

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote sidst redigeret af
                      #173

                      small new trial - Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma https://clinicaltrials.gov/study/NCT07588698

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote sidst redigeret af
                        #174

                        China's NMPA has approved epcoritamab (Epkinly) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (FL). This marks epcoritamab's first approval in China. https://medj.cn/articleDetails?id=728&module=innovationTracker

                        1 Reply Last reply
                        0

                        Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                        Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                        With your input, this post could be even better 💗

                        Tilmeld Log ind
                        Svar
                        • Svar som emne
                        Login for at svare
                        • Ældste til nyeste
                        • Nyeste til ældste
                        • Most Votes


                        • Log ind

                        • Har du ikke en konto? Tilmeld

                        • Login or register to search.
                        Powered by NodeBB Contributors
                        • First post
                          Last post
                        0
                        • Kategorier
                        • Seneste
                        • Etiketter
                        • Populære
                        • Verden
                        • Bruger
                        • Grupper